Engineered anti-TSLPR antibodies
View Patent ↗The invention relates to binding compounds that specifically bind to human TSLPR, as well as uses thereof, e.g., in the treatment of inflammatory disorders.
1. A binding compound that specifically binds human and cyno TSLPR comprising:
an antibody heavy chain variable region, or TSLPR-binding fragment thereof, comprising the CDR-H1 sequence of SEQ ID NO:1, the CDR-H2 sequence of SEQ ID NO:2 or SEQ ID NO:73, and the CDR-H3 sequence of SEQ ID NO:3; and
an antibody light chain variable region, or TSLPR-binding fragment thereof, comprising the CDR-L1 sequence of SEQ ID NO:4, the CDR-L2 sequence of SEQ ID NO:5, and the CDR-L3 sequence of SEQ ID NO:6 or SEQ ID NO:74.
2. The binding compound of claim 1 , comprising:
a heavy chain variable region comprising residues 1-116 of SEQ ID NO: 53 or of SEQ ID NO:51; and
a light chain variable region comprising residues 1-108 of SEQ ID NO: 54 or of SEQ ID NO:52.
3. The binding compound of claim 1 , wherein the binding compound is a TSLPR-binding antibody fragment selected from the group consisting of Fab, Fab′, Fab′-SH, Fv, scFv, F(ab′) 2 , and a diabody.
4. A composition comprising the binding compound of claim 1 in combination with a pharmaceutically acceptable carrier or diluent.